E

Evolus
D

EOLS

9.27000
USD
-0.03
(-0.27%)
مغلق
حجم التداول
16,704
الربح لكل سهم
0
العائد الربحي
-
P/E
-10
حجم السوق
597,688,710
أصول ذات صلة
B
BHC
-0.01500
(-0.24%)
6.17000 USD
NVS
NVS
-0.250
(-0.22%)
115.740 USD
REGN
REGN
-3.73
(-0.73%)
509.70 USD
TEVA
TEVA
-0.095
(-0.56%)
16.970 USD
ZTS
ZTS
2.070
(1.33%)
157.210 USD
المزيد
الأخبار المقالات

العنوان: Evolus

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.